Gothenburg-based BioTech firm VERIGRAFT has been awarded a €1.2 million Eurostars grant to guide the Precision Printed Personalised Tissue Therapies (PREPPER) mission, aiming to develop next-generation 3D-printed arterial grafts.
This initiative seeks to deal with important challenges in present graft know-how, together with restricted availability of human-donated supplies, poor integration, and excessive failure charges. The mission’s success might pave the way in which for preliminary human medical trials and future commercialisation, with potential functions extending past vascular grafts.
“This Eurostars grant is a serious milestone for VERIGRAFT and regenerative drugs. With PREPPER, we’re accelerating the way forward for personalised tissue therapies,” stated Dr Raimund Strehl, CTO of VERIGRAFT. “The worldwide vascular graft market is projected to exceed $4 billion by 2026, and PREPPER positions Europe on the forefront of 3D bioprinting and regenerative drugs.”
Based in 2004 by Jan Holgersson, VERIGRAFT is a biotechnology firm rooted within the Karolinska Institute, it has grown to develop into a forerunner in industrialised tissue engineering and superior regenerative drugs.
The corporate has a centered R&D pipeline of personalised tissues, concentrating on areas reminiscent of cardiovascular and neuronal illness. VERIGRAFT will commercialise a sequence of personalised tissue-engineered grafts on a worldwide market.
“VERIGRAFT provides a novel, breakthrough know-how within the subject of superior regenerative drugs. The know-how provides the chance to personalize tissues and organs. It will have the ability to carry a paradigm shift in transplantation drugs,” stated Petter Björquist PhD, Chief Govt Officer.
In an ongoing trial, VERIGRAFT has efficiently transplanted their personalised tissue-engineered vein, P-TEV™, into sufferers affected by power venous insufficiency (CVI)—a situation affecting the deep venous system that results in painful swelling and ulceration of the decrease legs. Notably, one affected person in Spain can now stroll unaided for the primary time in years and attend soccer matches.
Collaborating with Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska College Hospital (Sweden), VERIGRAFT will combine superior 3D printing, solution-blown fibre know-how, and personalised tissue engineering. The objective is to create customised vascular grafts that mimic pure arteries, providing superior sturdiness and seamless integration in comparison with present artificial alternate options.
The PREPPER mission has obtained funding from the Eurostars-3 joint programme, with Co-funding from the European Union’s Horizon Europe analysis and innovation programme. Eurostars is a part of the European Partnership on Modern SMEs.
By leveraging this grant and collaborative experience, VERIGRAFT goals to revolutionise the sphere of regenerative drugs, offering modern options for sufferers requiring arterial grafts and positioning Europe as a frontrunner in 3D bioprinting know-how.